Brinton LA, Moghissi KS, Westhoff CL, et al. Cancer risk among infertile women with androgen excess or menstrual disorders (including polycystic ovary syndrome). Fertil Steril 2010;94:1787–1792.
87.
Schildkraut JM, Schwingl PJ, Bastos E, et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88(Pt 1):554–559.
88.
Thomson RL, Buckley JD, Lim SS, et al. Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil Steril 2009;94:1812– 1916.
89.
Kerchner A, Lester W, Stuart SP, et al. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertil Steril 2009;91:207–212.
90.
Futterweit W. An endocrine approach obesity. In: Simopoulos AP, Vanltallie TB, Gullo SP, et al., eds. Obesity: new directions in assessment and management. New York: Charles Press, 1994: 96–121.
91.
Givens JR, Andersen RN, Wiser WL, et al. The effectiveness of two oral contraceptives in suppressing plasma androstenedione, testosterone, LH, and FSH, and in stimulating plasma testosterone-binding capacity in hirsute women. Am J Obstet Gynecol 1976;124:333–339.
92.
Raj SG, Raj MH, Talbert LM, et al. Normalization of testosterone levels using a low estrogen-containing oral contraceptive in women with polycystic ovary syndrome. Obstet Gynecol 1982;60:15–19.
93.
Wiebe RH, Morris CV. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol 1984;63:12–14.
94.
Wild RA, Umstot ES, Andersen RN, et al. Adrenal function in hirsutism. II. Effect of an oral contraceptive. J Clin Endocrinol Metab 1982;54:676–681.
95.
Marynick SP, Chakmakjian ZH, McCaffree DL, et al. Androgen excess in cystic acne. N Engl J Med 1983;308:981–986.
96.
Schiavone FE, Rietschel RL, Sgoutas D, et al. Elevated free testosterone levels in women with acne. Arch Dermatol 1983;119:799–802.
97.
Amin ES, El-Sayed MM, El-Gamel BA, et al. Comparative study of the effect of oral contraceptives containing 50 microgram of estrogen and those containing 20 microgram of estrogen on adrenal cortical function. Am J Obstet Gynecol 1980;137:831–833.
98.
Goldzieher JW. Polycystic ovarian disease. Fertil Steril 1981; 35:371–394.
99.
Rittmaster RS. Clinical review 73: medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 1995;80:2559–2563.
100.